Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

An Operating Partner at SV Health Investors, she describes how the company came together after reaching out to Cardiff University Professors John Atack and Simon Ward. She highlights how unusual it is to have clinical proof of concept data already while raising a series A, and why she believes Draig will make a difference for patients.